Your browser is no longer supported. Please, upgrade your browser.
DCPH [NASD]
Deciphera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.00 Insider Own0.60% Shs Outstand56.39M Perf Week-10.97%
Market Cap2.82B Forward P/E- EPS next Y-4.41 Insider Trans-41.22% Shs Float40.31M Perf Month-11.22%
Income-271.00M PEG- EPS next Q-1.13 Inst Own75.40% Short Float9.28% Perf Quarter-10.83%
Sales22.60M P/S124.73 EPS this Y-58.90% Inst Trans0.11% Short Ratio10.99 Perf Half Y-3.49%
Book/sh10.09 P/B4.96 EPS next Y8.50% ROA-40.10% Target Price76.42 Perf Year-25.46%
Cash/sh9.69 P/C5.17 EPS next 5Y21.00% ROE-45.00% 52W Range33.10 - 71.11 Perf YTD-12.27%
Dividend- P/FCF- EPS past 5Y- ROI-36.70% 52W High-29.59% Beta1.49
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin99.60% 52W Low51.27% ATR2.63
Employees255 Current Ratio9.30 Sales Q/Q- Oper. Margin- RSI (14)33.84 Volatility4.52% 4.91%
OptionableYes Debt/Eq0.00 EPS Q/Q11.90% Profit Margin- Rel Volume1.42 Prev Close51.17
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume340.52K Price50.07
Recom1.80 SMA20-10.24% SMA50-15.12% SMA200-7.14% Volume481,925 Change-2.15%
Dec-03-20Initiated Stifel Buy $75
Sep-14-20Resumed JP Morgan Neutral $52
May-07-20Downgrade Nomura Buy → Neutral $84 → $60
Mar-04-20Initiated Barclays Overweight $70
Dec-20-19Reiterated Jefferies Buy $53 → $77
Oct-29-19Upgrade SVB Leerink Underperform → Mkt Perform $29 → $34
Oct-22-19Initiated JMP Securities Mkt Outperform
Oct-03-19Initiated H.C. Wainwright Buy $60
Sep-30-19Initiated Jefferies Buy $47
Jul-18-19Initiated Deutsche Bank Buy $42
Dec-31-18Upgrade B. Riley FBR Neutral → Buy $27 → $34
Sep-25-18Initiated Leerink Partners Underperform
Aug-29-18Initiated Raymond James Outperform $47
Jul-05-18Initiated SunTrust Buy
Jun-19-18Downgrade B. Riley FBR, Inc. Buy → Neutral $43
Feb-16-18Initiated B. Riley FBR, Inc. Buy $43
Oct-23-17Initiated Piper Jaffray Overweight $35
Oct-23-17Initiated Nomura Buy
Oct-23-17Initiated JP Morgan Overweight $30
Oct-23-17Initiated JMP Securities Mkt Outperform $38
Jan-11-21 07:00AM  
Jan-05-21 07:23AM  
Dec-20-20 10:04PM  
Dec-18-20 12:14PM  
Dec-01-20 10:04AM  
Nov-30-20 07:00AM  
Nov-24-20 04:01PM  
Nov-23-20 07:00AM  
Nov-11-20 07:01AM  
07:00AM  
Nov-10-20 07:00AM  
05:29AM  
Nov-09-20 10:18AM  
Nov-06-20 10:31PM  
Nov-05-20 04:01PM  
02:45PM  
Oct-28-20 07:00AM  
Sep-22-20 04:23PM  
Sep-20-20 09:12AM  
Sep-18-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 12:48AM  
Aug-17-20 04:30PM  
Aug-06-20 08:40AM  
Aug-05-20 08:01AM  
Aug-04-20 06:25PM  
04:05PM  
Jul-29-20 07:00AM  
Jul-20-20 10:39AM  
07:30AM  
Jul-14-20 07:00AM  
Jul-12-20 08:15PM  
Jul-09-20 08:01AM  
Jul-02-20 04:01PM  
Jun-22-20 07:00AM  
Jun-17-20 07:36PM  
Jun-11-20 07:00AM  
Jun-08-20 07:30AM  
02:56AM  
Jun-03-20 07:11AM  
May-29-20 08:05AM  
08:00AM  
May-27-20 07:00AM  
May-26-20 07:06AM  
May-23-20 07:34AM  
May-18-20 04:16PM  
12:22PM  
06:15AM  
May-15-20 06:34PM  
May-12-20 06:53AM  
May-08-20 09:25AM  
May-06-20 12:01PM  
May-05-20 06:35PM  
04:01PM  
May-04-20 01:36PM  
08:45AM  
Apr-28-20 11:19AM  
07:00AM  
Apr-23-20 09:06AM  
Mar-28-20 09:10PM  
Mar-09-20 05:15PM  
04:01PM  
02:30PM  
Mar-02-20 07:00AM  
Feb-20-20 07:00AM  
Feb-19-20 04:01PM  
Feb-13-20 10:12PM  
01:36PM  
10:31AM  
08:05AM  
Feb-12-20 04:14PM  
04:01PM  
Jan-13-20 09:00AM  
Jan-11-20 06:09PM  
Jan-06-20 07:00AM  
Jan-02-20 06:40AM  
Dec-17-19 07:56AM  
Dec-16-19 07:00AM  
Dec-05-19 03:47PM  
Dec-04-19 04:05PM  
Nov-26-19 07:00AM  
07:00AM  
Nov-22-19 08:00PM  
Nov-13-19 04:30PM  
07:00AM  
Nov-04-19 05:15PM  
04:01PM  
Nov-01-19 10:24AM  
Oct-30-19 10:15AM  
Oct-29-19 12:30PM  
07:32AM  
Oct-28-19 06:06PM  
12:30PM  
07:00AM  
Oct-17-19 10:21AM  
Oct-16-19 04:34PM  
Oct-15-19 05:07PM  
Oct-04-19 09:00AM  
05:56AM  
Oct-02-19 07:00AM  
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taylor Michael DouglasDirectorJan 04Option Exercise1.8919,00035,91019,000Jan 06 04:10 PM
Taylor Michael DouglasDirectorJan 04Sale56.4519,0001,072,4970Jan 06 04:10 PM
Sherman Matthew LEVP & Chief Medical OfficerDec 09Option Exercise34.432077,12737,418Dec 11 04:10 PM
Taylor Michael DouglasDirectorDec 01Option Exercise1.8919,00035,91019,000Dec 03 04:15 PM
Taylor Michael DouglasDirectorDec 01Sale60.9019,0001,157,1420Dec 03 04:15 PM
Sherman Matthew LEVP & Chief Medical OfficerNov 16Option Exercise34.432,69792,85837,211Nov 18 07:31 PM
Taylor Michael DouglasDirectorNov 04Option Exercise1.8915,00028,35015,000Nov 06 04:00 PM
Taylor Michael DouglasDirectorNov 04Sale64.8015,000971,9870Nov 06 04:00 PM
Taylor Michael DouglasDirectorNov 02Option Exercise1.8923,31544,06523,315Nov 04 04:10 PM
Taylor Michael DouglasDirectorNov 02Sale57.6423,3151,343,9260Nov 04 04:10 PM
Bristol James ArthurDirectorOct 09Option Exercise1.8923,54144,49223,541Oct 13 04:20 PM
Bristol James ArthurDirectorOct 09Sale53.5723,5411,261,0690Oct 13 04:20 PM
Taylor Michael DouglasDirectorOct 01Option Exercise1.89125,000236,250125,000Oct 05 04:00 PM
Taylor Michael DouglasDirectorOct 01Sale51.60125,0006,450,4840Oct 05 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 14Option Exercise1.893,0005,67010,040Sep 16 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 14Sale50.013,000150,0367,040Sep 16 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 10Option Exercise1.893,0005,67010,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 10Sale47.713,000143,1267,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 08Option Exercise1.896,00011,34013,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 08Sale45.496,000272,9297,040Sep 10 08:29 PM
Hoerter Steven L.President and CEOAug 20Option Exercise25.401874,75042,767Aug 24 04:00 PM
Flynn Daniel LeeChief Scientific OfficerAug 10Option Exercise1.899,02917,065237,475Aug 12 04:00 PM
Flynn Daniel LeeChief Scientific OfficerJul 22Option Exercise1.89130,000245,700228,446Jul 24 04:00 PM
Hoerter Steven L.President and CEOJul 20Option Exercise25.401884,77542,580Jul 22 04:00 PM
Bristol James ArthurDirectorJul 09Option Exercise1.8923,54144,49223,541Jul 13 04:11 PM
Bristol James ArthurDirectorJul 09Sale54.9923,5411,294,6340Jul 13 04:11 PM
Taylor Michael DouglasDirectorJul 06Option Exercise1.8927,54452,05827,544Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 06Sale55.2227,5441,520,8730Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 02Option Exercise1.8948,24591,18348,245Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 02Sale56.6948,2452,734,9650Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 01Option Exercise1.8949,21193,00949,211Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 01Sale58.8749,2112,896,8890Jul 06 06:16 PM
Hoerter Steven L.President and CEOJun 18Option Exercise25.401874,75042,392Jun 19 04:00 PM
Allen Patricia LDirectorJun 05Option Exercise25.735,635144,9895,635Jun 05 04:05 PM
Allen Patricia LDirectorJun 05Sale55.905,635314,9990Jun 05 04:05 PM
Allen Patricia LDirectorJun 03Option Exercise25.736,365163,7716,365Jun 05 04:05 PM
Allen Patricia LDirectorJun 03Sale59.146,365376,4500Jun 05 04:05 PM
Hoerter Steven L.President and CEOMay 28Option Exercise25.401884,77542,205Jun 01 04:05 PM
Kelly Thomas PatrickChief Financial OfficerMay 11Option Exercise1.8912,00022,68019,040May 13 04:05 PM
Kelly Thomas PatrickChief Financial OfficerMay 11Sale55.1912,000662,2407,040May 13 04:05 PM
Taylor Michael DouglasDirectorApr 28Option Exercise1.8925,00047,25025,000Apr 30 04:05 PM
Taylor Michael DouglasDirectorApr 28Sale56.9025,0001,422,4900Apr 30 04:05 PM
Hoerter Steven L.President and CEOApr 21Option Exercise25.401874,75042,017Apr 23 04:10 PM
Taylor Michael DouglasDirectorApr 17Option Exercise1.8923,89245,15623,892Apr 21 04:05 PM
Taylor Michael DouglasDirectorApr 17Sale46.6723,8921,115,1500Apr 21 04:05 PM
Taylor Michael DouglasDirectorApr 14Option Exercise1.891,1082,0941,108Apr 16 04:05 PM
Taylor Michael DouglasDirectorApr 14Sale46.711,10851,7530Apr 16 04:05 PM
Bristol James ArthurDirectorApr 09Option Exercise1.8923,54244,49423,542Apr 13 07:47 PM
Bristol James ArthurDirectorApr 09Sale43.8323,5421,031,8400Apr 13 07:47 PM
Taylor Michael DouglasDirectorApr 01Option Exercise1.8975,000141,75075,000Apr 03 04:10 PM
Taylor Michael DouglasDirectorApr 01Sale37.5775,0002,817,5580Apr 03 04:10 PM
Hoerter Steven L.President and CEOMar 18Option Exercise25.402,25057,15054,250Mar 20 05:49 PM
Allen Patricia LDirectorJan 24Sale66.1325,0001,653,3250Jan 28 04:13 PM
Martin Daniel C.Chief Commercial OfficerJan 22Option Exercise36.1026,999974,66443,999Jan 24 04:10 PM
Martin Daniel C.Chief Commercial OfficerJan 22Sale67.1826,9991,813,70917,000Jan 24 04:10 PM